E2814 Market

“E2814 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about E2814 for Alzheimer’s disease in Japan. A detailed picture of the E2814 for Alzheimer’s disease in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the E2814 for Alzheimer’s disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the E2814 market forecast analysis for Alzheimer’s disease in Japan, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Alzheimer’s disease.

Drug Summary

E2814 is a humanized, high-affinity monoclonal IgG1 antibody that recognizes the anti-microtubule binding region (MTBR) tau drug. The antibody binds to extracellular tau, prevents cell-to-cell propagation of pathogenic species, and mediates clearance by microglia. As revealed by epitope mapping, E2814 and its murine precursor, 7G6, are antibodies bi-epitopic for 4R and mono-epitopic for 3R tau isoforms because they bind to sequence motif HVPGG. Functionally, both antibodies inhibited tau aggregation and treated Alzheimer’s disease.

E2814 is being developed as a disease-modifying agent for tauopathies including sporadic Alzheimer’s. Phase I clinical studies are underway. E2814 was discovered as part of the research collaboration between Eisai and University College London. It is designed to prevent the spreading of tau seeds within the brains of affected individuals. Currently, the drug is being assessed in two Phase II/III studies for the treatment of dominantly inherited Alzheimer's disease (DIAD), conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).

Gain a deeper understanding of the Market with DelveInsight’s detailed report @ Alzheimer’s Disease Treatment Market Size

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the E2814 description, mechanism of action, dosage and administration, research and development activities in Alzheimer’s disease.
• Elaborated details on E2814 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the E2814 research and development activities in Alzheimer’s disease across Japan.
• The report also covers the patents information with expiry timeline around E2814.
• The report contains forecasted sales of E2814 for Alzheimer’s disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Alzheimer’s disease.
• The report also features the SWOT analysis with analyst views for E2814 in Alzheimer’s disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Alzheimer’s Disease Prevalence

E2814 Analytical Perspective by DelveInsight

• In-depth E2814 Market Assessment

This report provides a detailed market assessment of E2814 for Alzheimer’s disease in Japan. This segment of the report provides forecasted sales data from 2031 to 2032.

• E2814 Clinical Assessment

The report provides the clinical trials information of E2814 for Alzheimer’s disease covering trial interventions, trial conditions, trial status, start and completion dates.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Alzheimer’s Disease Treatment Drugs

Report Highlights  

• In the coming years, the market scenario for Alzheimer’s disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence E2814 dominance.
• Other emerging products for Alzheimer’s disease are expected to give tough market competition to E2814 and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of E2814 in Alzheimer’s disease.
• Our in-depth analysis of the forecasted sales data of E2814 from 2031 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the E2814 in Alzheimer’s disease. 

Key Questions

• What is the product type, route of administration and mechanism of action of E2814?
• What is the clinical trial status of the study related to E2814 in Alzheimer’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the E2814 development?
• What are the key designations that have been granted to E2814 for Alzheimer’s disease?
• What is the forecasted market scenario of E2814 for Alzheimer’s disease?
• What are the forecasted sales of E2814 in Japan?  
• What are the other emerging products available and how are these giving competition to E2814 for Alzheimer’s disease?
• Which are the late-stage emerging therapies under development for the treatment of Alzheimer’s disease?